Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy
- Registration Number
- NCT01016665
- Lead Sponsor
- Federal University of São Paulo
- Brief Summary
Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment.
Although traditionally endocrine therapy is based on hormonal receptors status (estrogen - ER and progesterone- PR), some patients become hormone resistant. In order to identify a possible profile associated to hormonal resistance, some biomarkers have been assessed after short period primary hormone therapy (HT).
Objectives: To compare the expression of Ki-67, Bcl2, Bax, Bak, ER and e PR in postmenopausal women with ER positive invasive ductal carcinomas (IDC), prior and after tamoxifen and anastrozole in short term hormone therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 71
Inclusion Criteria
- Invasive breast cancer post-menopausal women
- Estrogen and/or progesterone receptor positive
Exclusion Criteria
- Patients with endocrine disease
- Hormone therapy users or those who had been pregnant in the last 12 months before the diagnosis
- Patients with a negative expression for estrogen and/or progesterone receptors
- Women with a history of thromboembolism
- Patients who had previously undergone any treatment for breast cancer
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Anastrozole Anastrozole Anastrozole 1mg 26 days Placebo Anastrozole Placebo Tamoxifen Anastrozole Tamoxifen 20 mg day 26 days
- Primary Outcome Measures
Name Time Method Expression of progesterone end of the study (june 2008)
- Secondary Outcome Measures
Name Time Method Expression of Ki-67 end of the study (june 2008)
Trial Locations
- Locations (1)
Sao Paulo Federal University
🇧🇷Sao Paulo, Brazil